127 related articles for article (PubMed ID: 12127713)
1. In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus.
Muñoz Bellido JL; Gutiérrez Zufiaurre MN; Sánchez Hernández FJ; Yagüe Guirao G; Segovia Hernández M; García-Rodríguez JA
Int J Antimicrob Agents; 2002 Jul; 20(1):61-4. PubMed ID: 12127713
[TBL] [Abstract][Full Text] [Related]
2. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of telithromycin, quinupristin/dalfopristin, linezolid and comparator antimicrobial agents against Staphylococcus aureus clinical isolates.
Millán L; Cerdá P; Rubio MC; Goñi P; Canales M; Capilla S; Oca M; Gómez-Lus R
J Chemother; 2004 Jun; 16(3):230-7. PubMed ID: 15330317
[TBL] [Abstract][Full Text] [Related]
4. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.
Bråbäck M; Riesbeck K; Forsgren A
Antimicrob Agents Chemother; 2002 Apr; 46(4):1114-6. PubMed ID: 11897601
[TBL] [Abstract][Full Text] [Related]
5. Activities of clindamycin, synercid, telithromycin, linezolid, and mupirocin against Gram-positive coccal strains resistant to erythromycin in Korea.
Kwon AR; Yoon EJ; Yoon JM; Kim H; Shim MJ; Choi EC
Arch Pharm Res; 2007 Jul; 30(7):840-3. PubMed ID: 17703735
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum.
Sánchez Hernández J; Mora Peris B; Yagüe Guirao G; Gutiérrez Zufiaurre N; Muñoz Bellido JL; Segovia Hernández M; García Rodríguez JA
Int J Antimicrob Agents; 2003 Nov; 22(5):492-6. PubMed ID: 14602367
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
Abb J
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):319-21. PubMed ID: 12151194
[TBL] [Abstract][Full Text] [Related]
8. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 2001 Sep; 45(9):2604-8. PubMed ID: 11502536
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.
Betriu C; Redondo M; Boloix A; Gómez M; Culebras E; Picazo JJ
J Antimicrob Chemother; 2001 Dec; 48(6):911-3. PubMed ID: 11733478
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
[TBL] [Abstract][Full Text] [Related]
11. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Mendes RE; Moet GJ; Janechek MJ; Jones RN
Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci.
John MA; Pletch C; Hussain Z
J Antimicrob Chemother; 2002 Dec; 50(6):933-8. PubMed ID: 12461014
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
16. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.
Grohs P; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 2003 Jan; 47(1):418-20. PubMed ID: 12499229
[TBL] [Abstract][Full Text] [Related]
17. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
Coskun-Ari FF; Bosgelmez-Tinaz G
Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
19. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
20. Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains.
Clark C; Kosowska-Shick K; McGhee P; Dewasse B; Beachel L; Appelbaum PC
Antimicrob Agents Chemother; 2009 Jul; 53(7):3118-21. PubMed ID: 19433566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]